Related Experiment Video
Updated: Dec 10, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Treating non-small cell lung cancer with selumetinib: an up-to-date drug evaluation
Evgeny N Imyanitov1,2,3,4,5, Evgeny V Levchenko1,3, Ekatherina S Kuligina1
1Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology , St.-Petersburg, 197758, Russia.
Introduction:
RAS-RAF-MEK-ERK signaling is implicated in tumor development by promoting cell proliferation and other cancer hallmarks. MEK1/2 kinases are up-regulated in the majority of human cancers due to activation of tyrosine kinase receptors, RAS proteins, BRAF kinase, or some other members of the MAPK pathway. Targeting of MEK1/2 kinases may counterbalance cancer progression.
Areas Covered:
The authors analyze the scientific publications relevant to selumetinib (AZD6244, ARRY-142886) systematically and provide their expert opinion.
Expert Opinion:
Selumetinib is an oral selective allosteric inhibitor of MEK1 and MEK2 kinases. Single-agent selumetinib is usually administered in hydrogen sulfate capsules 75 mg twice a day; combination with other therapeutic compounds may or may not require reduced dosing of this drug. The established dose for pediatric patients is 25 mg per square meter twice a day. Selumetinib was extensively evaluated in non-small cell lung cancer (NSCLC) patients. Studies utilizing this drug as a monotherapy did not confirm its efficacy toward NSCLC. A phase II trial showed that the addition of selumetinib to docetaxel improved response rates and progression-free survival (PFS) in chemotherapy-pretreated KRAS-mutated NSCLC patients; however, a subsequent phase III study did not confirm these findings. There are several highly successful non-NSCLC selumetinib trials involving, e.g., patients with neurofibromatosis type 1 related tumors and children with low-grade BRAF-driven gliomas.
Insights
Selumetinib, a MEK1/2 inhibitor, shows promise in specific cancers like neurofibromatosis type 1 and pediatric gliomas. However, its efficacy as a monotherapy in non-small cell lung cancer (NSCLC) was not confirmed.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- The RAS-RAF-MEK-ERK pathway is crucial in tumor development, driving cell proliferation.
- MEK1/2 kinases are frequently overexpressed in human cancers, making them a therapeutic target.
- Inhibition of MEK1/2 kinases offers a strategy to counteract cancer progression.
Purpose of the Study:
- To systematically review scientific literature on selumetinib (AZD6244, ARRY-142886).
- To provide expert opinion on the clinical utility and efficacy of selumetinib.
- To evaluate selumetinib's role in various cancer types, including non-small cell lung cancer (NSCLC).
Main Methods:
- Systematic analysis of scientific publications related to selumetinib.
- Expert review and opinion synthesis based on available clinical trial data.
- Evaluation of selumetinib's efficacy in monotherapy and combination treatments across different cancer types.
Main Results:
- Selumetinib is an oral, selective, allosteric inhibitor of MEK1 and MEK2 kinases.
- Monotherapy with selumetinib did not demonstrate efficacy in non-small cell lung cancer (NSCLC) patients.
- Combination therapy showed potential in a Phase II trial for KRAS-mutated NSCLC, but this was not confirmed in a Phase III trial.
- Successful outcomes were observed in trials for neurofibromatosis type 1 related tumors and pediatric low-grade gliomas.
Conclusions:
- Selumetinib is an approved MEK inhibitor with established dosing for adults and pediatric patients.
- While not effective as monotherapy for NSCLC, it has shown success in specific genetic contexts and rare tumor types.
- Further research may explore optimal combinations and patient selection for selumetinib therapy.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
08:52Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
